Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors: Assessment of Safety and Efficacy

NCT07404176 is registered in ClinicalTrials.gov with Tata Memorial Hospital as lead sponsor.

NCT NCT07404176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07404176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors: Assessment of Safety and Efficacy
Lead sponsor
Tata Memorial Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2026
Completion date
February 28, 2029
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic neuroendocrine tumors, neuroendocrine neoplasms (tumours), neuroendocrine tumors